CPACC: The Real Magic Weight Loss Pill?

Decoding the hype behind CPACC

Midjourney rendition of this article.

It’s very rare that we receive a pill that can solve a major health-related problem or function as a powerful supplement. The temptation and hope for such an easy solution have resulted in many such claims of “magic pills” in the supplements industry. However, every once in a while, a true scientific breakthrough occurs, and we are handed such a miracle pill. CPACC for weight loss may be such a case.

Introduction:
Obesity has become a global epidemic. According to the Centers for Disease Control and Prevention, over 40% of Americans are obese, leading to a myriad of health complications ranging from heart disease to diabetes and is a potent risk factor for many other illnesses. Beyond the health implications, obesity also places a significant economic burden on healthcare systems and can significantly reduce quality of life. In this context, the promise of a weight loss pill that doesn't require extreme dieting and exercise (or really any discipline) sounds too good to be true. Even for a fitness junky (like myself), such a tool would be extremely tempting for gaining a leaner physique. Enter CPACC, a novel drug developed by researchers at the University of Texas Health Science Center at San Antonio.

Figure 1. Graphical Abstract from CPACC manuscript published in Cell Reports (Madris, 2023). This figure describes how limiting mitochondrial Mg2+ enhances bioenergetics.

Is CPACC the game-changer it's touted to be?

The Claim:
CPACC's unique approach to weight loss revolves around the body's magnesium uptake, a crucial component in cellular energy production. CPACC inhibits this magnesium uptake to replicate the effects observed in mice when a gene controlling magnesium flow (MRS2) is deleted. Mice with knocked out (removed) MSR2 remained slim even when consuming a western diet rich in fats and sugars as shown in Figure 2 (Madaris, 2023). The hope is that CPACC can produce similar results in humans. This would set it apart from other weight loss pills that control appetite such as Ozempic or stimulants that amplify metabolism.

Figure 2. Blocking mitochondrial Mg2+ uptake prevents diet-induced obesity (A) Body weight change over a 30-week diet period. Data fit with a Gompertz growth curve (n = 4–16 mice/group). (B) Weight gained during the dietary regimen.

Impact (Why You May Care):
Beyond weight loss, CPACC promises broader health benefits. It offers potential solutions for cardiometabolic diseases, such as heart attacks and strokes, and might reduce the incidence of liver cancer following fatty liver disease. Unlike many existing weight loss medications that target insulin resistance or production, CPACC focuses on cellular magnesium flow, providing a novel approach to weight management.

Are we sure this is real?:
While the preliminary evidence from animal studies is compelling, we should still approach CPACC with a healthy dose of skepticism. After all, we have been curing cancer and diabetes in mice for decades. Further, many drugs show promise in early trials but fail to replicate results in larger, more diverse populations. Moreover, the safety profile of CPACC remains largely unknown. Every medication comes with potential side effects, and until comprehensive human trials are conducted, it's unclear what risks CPACC might pose. It's also worth noting that while animal models are valuable for initial drug testing, human physiology can differ in significant ways, making it essential to interpret such results with a massive grain of salt.

What Comes Next:
The pipeline from a ‘promising drug candidate’ to an ‘approved medication’ is long and fraught with challenges. CPACC is still in its experimental stages, and while the initial results are promising, rigorous clinical trials are needed to determine its efficacy, safety, and potential side effects in humans. As with all new drugs, it's crucial to balance optimism with caution. The team at the University of Texas Health Science Center is dedicated to this endeavor, with human trials planned in the coming months (NYPost). But until then, the true potential of CPACC remains an open question.

References:

Madaris et al., 2023, "Limiting Mrs2-dependent mitochondrial Mg2+ uptake induces metabolic programming in prolonged dietary stress", Cell Reports 42, 112155.

“Overweight & Obesity”, https://www.cdc.gov/obesity/data/surveillance.html#NPAO, Accessed August 14, 2023.

“Ozempic for weight loss: Does it work, and what do experts recommend”, https://health.ucdavis.edu, Accessed August 14, 2023.

"Researchers are one step closer to weight loss wonder pill", NY Post, August 8, 2023.

"Drug that spurs weight loss without dieting in the works", NY Post, March 23, 2023.